Highlights

  • Oneview introduced Bedside Hub in May 2026 as a managed hardware and services platform supporting Epic MyChart Bedside TV.
  • FY25 revenue increased 21% to EUR 12.0 million, while recurring revenue rose 7% to EUR 7.7 million.
  • Oneview had 14,880 live endpoints at the end of 2025, representing an 11% increase over the year.
  • A roughly A$19 million placement in March 2026 increased the company’s funding capacity as it pursued further US hospital opportunities.
  • Bedside Hub, Ovie and existing distribution partnerships could broaden Oneview’s revenue mix, although contract conversion and cash usage remain important considerations.

Oneview Healthcare (ASX:ONE) has spent more than a decade developing technology around one of the most visible but often overlooked pieces of hospital infrastructure: the screen positioned beside a patient’s bed.

The Irish-founded, ASX-listed healthcare technology company has gradually transformed that screen from a basic entertainment device into a digital interface connecting patients with hospital services, clinical workflows and information.

Its strategy broadened further in May 2026 with the introduction of Bedside Hub, a managed hardware and services offering designed to run Epic MyChart Bedside TV through hospital room televisions.

Rather than representing a standalone announcement-driven story, Bedside Hub can be viewed as part of Oneview’s longer-term effort to expand beyond its core software platform and generate additional revenue from hardware, integration, monitoring and recurring services.

The central question is whether that broader product suite can translate into larger hospital contracts, faster recurring revenue growth and a more sustainable financial model.

Oneview’s Role Inside the Hospital Room

Oneview Healthcare is a digital health business focused primarily on the US healthcare market. The company has been listed on the ASX since 2016 and reports its financial results in euros, with a 31 December financial year-end.

Its core technology acts as a digital care-experience layer between patients and hospital systems.

Through bedside screens, patients can access entertainment, order meals, participate in virtual care, interact with nurse-call functions and use other hospital services from a single interface.

For hospitals, the platform provides a digital entry point into the patient room while connecting with existing clinical and operational infrastructure.

The US has become Oneview’s main market, with its platform operating across more than 80 hospitals.

At the end of 2025, the company had 14,880 live endpoints, up 11% over the year. It had also added 18 new customer logos over the preceding three years.

Distribution partnerships form an important part of Oneview’s commercial strategy. Its reseller relationship with Baxter International was extended to Canada in 2024, broadening access to hospitals across North America without requiring Oneview to build an entirely standalone sales network.

How Bedside Hub Broadens the Model

Bedside Hub represents an extension of Oneview’s existing role in the patient room.

Introduced in May 2026, the product combines healthcare-grade hardware with cloud-based device management to support Epic MyChart Bedside TV on hospital televisions.

For hospitals already using Epic infrastructure, the proposition is relatively straightforward: MyChart Bedside functionality can be delivered through the television already positioned in the room rather than relying exclusively on separate tablet hardware.

Importantly, Oneview is offering more than the physical device.

Bedside Hub combines hardware, cloud device management and a managed-service layer covering installation, Epic integration testing and continuous monitoring.

That structure potentially opens revenue streams beyond traditional software licensing by adding services connected with deployment, device management and ongoing support.

At the time the product was introduced, management said Oneview was already in active contract negotiations for an approximately 1,100-bed opportunity and had received additional inquiries.

No first Bedside Hub contract or pricing economics had been disclosed at that stage, meaning the commercial significance of the product still depended on converting interest into signed agreements.

FY25 Revenue Increased While Losses Continued

Oneview’s audited results for the year ended 31 December 2025 showed continued revenue growth alongside ongoing operating losses.

Revenue increased 21% to EUR 12.0 million.

Recurring revenue, which is particularly relevant for assessing the development of the software business, increased 7% to EUR 7.7 million.

The difference between total revenue growth and recurring revenue growth reflected a larger contribution from hardware and services.

That change in mix also affected profitability. Gross margin declined to 64% from 67% in the prior year as lower-margin hardware activity represented a greater share of revenue.

The operating Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) loss narrowed 8% to EUR 8.1 million.

Oneview finished 2025 with EUR 4.6 million in cash, highlighting the importance of funding as it continued investing in product development and commercial expansion.

In March 2026, the company secured a two-tranche placement of approximately A$19 million.

The first tranche of A$12 million settled on 24 March 2026 at 19 cents per share, increasing pro-forma cash to approximately EUR 10.1 million.

The additional funding provided more capacity to pursue hospital deployments and develop its broader product pipeline, although the company’s continuing operating losses mean cash utilisation remains an important metric.

Why Bedside Hub Matters Strategically

The longer-term relevance of Bedside Hub lies in how it potentially changes Oneview’s revenue model.

Historically, the company’s investment case has centred on deploying its care-experience software across increasing numbers of hospital beds and growing associated recurring revenue.

Bedside Hub adds another potential layer.

A hospital using the product may require hardware, installation, integration, cloud device management and ongoing monitoring. That creates an opportunity for Oneview to earn revenue from multiple components of a deployment rather than relying only on its core application software.

The product also places Oneview alongside an established electronic health record ecosystem already used extensively across US hospitals.

That positioning could reduce some of the friction associated with introducing entirely independent technology into complex hospital environments.

However, strategic alignment and commercial conversion are different things.

The ultimate significance of Bedside Hub will depend on how many hospitals sign contracts, the number of beds covered, implementation timelines and the recurring economics attached to each deployment.

A Broader Digital Care Platform

Bedside Hub is not Oneview’s only attempt to widen its addressable market.

In early 2026, the company introduced Ovie, a digital care assistant intended to extend its platform toward workflow automation and artificial intelligence-assisted care.

The addition reflects a broader shift from treating the bedside screen primarily as a patient interface toward using it as part of a wider digital hospital environment.

If hospital operators increasingly look for integrated platforms spanning patient engagement, clinical communication and workflow support, Oneview could potentially sell additional products into its existing hospital relationships.

The company has also been targeting close to 18,000 live endpoints by the end of 2026.

Growth in endpoints matters because each additional deployment can enlarge the base through which Oneview can sell software, services and newer products.

Its relationships with Baxter and a large US group purchasing organisation could also help it reach hospital systems without carrying the full cost of a direct distribution infrastructure.

Contract Conversion Is the Key Commercial Test

Oneview operates in a market where individual customer wins can involve hundreds or thousands of hospital beds.

That creates meaningful operating leverage when deployments scale, but it also means sales cycles can be lengthy.

Hospitals typically have complex procurement processes, integration requirements and technology budgets, which can delay the period between initial discussions and recognised revenue.

This makes Bedside Hub contract conversion particularly important.

The approximately 1,100-bed opportunity referenced by management illustrated the potential scale of individual deployments, but commercial value cannot be assumed until agreements are executed.

The company’s existing endpoint base gives it an established presence in the market, but investors will ultimately need evidence that newer offerings can meaningfully lift recurring and total revenue.

Recurring Revenue Remains an Important Indicator

Oneview’s FY25 recurring revenue increased 7% to EUR 7.7 million, compared with the 21% increase in total revenue to EUR 12.0 million.

That difference is important when assessing the quality of growth.

Hardware and implementation services can increase reported revenue, but they may carry lower margins and may not repeat at the same level each year.

Recurring software and managed-service revenue can provide greater visibility over future income.

Bedside Hub therefore becomes more strategically interesting if the managed-service component produces ongoing revenue in addition to upfront hardware and deployment income.

An acceleration in recurring revenue growth would provide evidence that Oneview is increasing the proportion of predictable revenue generated from its installed hospital base.

Financial Risks Have Not Disappeared

Oneview continues to operate at a loss, making cash management a central part of the investment case.

The FY25 operating EBITDA loss of EUR 8.1 million remained large relative to the EUR 4.6 million cash balance recorded at the end of that year.

The March 2026 capital raising materially increased liquidity, with pro-forma cash reaching approximately EUR 10.1 million after the first tranche.

Nevertheless, the longer-term funding position will depend on how quickly revenue growth translates into lower operating losses and reduced cash consumption.

A slower sales cycle or delayed customer deployments could increase the possibility of additional capital requirements.

Customer budget pressure represents another risk.

Oneview decommissioned around 900 endpoints in Australia during 2025 after a customer reduced spending, illustrating how hospital cost decisions can directly affect installed capacity.

A higher contribution from hardware can also pressure gross margins, as demonstrated by the decline from 67% to 64% in FY25.

Digital Hospital Spending Provides the Broader Opportunity

Hospitals continue to face pressure to improve patient experience while managing workforce constraints and increasingly complex technology systems.

These challenges are encouraging healthcare providers to digitise more of the patient journey and integrate clinical, administrative and communication functions.

The bedside represents one part of that transition.

Patient-room technology can provide access to medical information, communication tools, entertainment, meal ordering, education and virtual care while reducing the need for separate devices and interfaces.

Oneview’s opportunity lies in providing an integrated platform that works with existing hospital infrastructure rather than requiring healthcare providers to replace their core systems.

Competition remains substantial, however.

Hospitals can choose among alternative patient-engagement platforms, smart-room technologies, tablet-based systems and solutions developed internally or by larger healthcare technology providers.

Product integration and ease of deployment therefore need to translate into measurable operational value for hospitals.

What Matters for Oneview From Here

Several operating indicators can help determine whether Oneview’s broader product strategy is translating into financial progress.

Contract conversion for Bedside Hub is one of the clearest measures. Signed hospital agreements would provide evidence that the product is progressing from market interest to commercial deployment.

Recurring revenue growth is equally important.

The FY25 increase of 7% provides a useful baseline against which future periods can be assessed, particularly as Bedside Hub and Ovie are introduced into the commercial mix.

Endpoint growth will also remain relevant because a larger installed base expands Oneview’s potential audience for additional products and recurring services.

Investors can also monitor gross margin as the revenue mix evolves. Further expansion in lower-margin hardware revenue without corresponding growth in recurring services could weigh on overall economics.

Finally, cash utilisation and the operating EBITDA trajectory will help indicate whether revenue growth is moving the company toward a more sustainable funding position.

Conclusion

Oneview Healthcare is gradually broadening its role inside the hospital room.

Its core platform already operates across more than 80 hospitals and reached 14,880 live endpoints at the end of 2025. Bedside Hub adds managed hardware, cloud device management, integration and monitoring to that existing software base, while Ovie extends the product portfolio further into digital workflow and AI-assisted care.

Financially, FY25 revenue increased 21% to EUR 12.0 million and recurring revenue rose 7% to EUR 7.7 million, although the company continued to report an operating EBITDA loss of EUR 8.1 million.

The March 2026 capital raising gave Oneview additional financial capacity, but the next phase of the business depends less on announcing new products and more on translating them into contracted hospital deployments and recurring revenue.

Bedside Hub therefore represents an important extension of Oneview’s strategy, but its longer-term contribution will be determined by customer adoption, contract economics, margin performance and the company’s ability to reduce its reliance on external funding over time.